藥物警訊 | 合法藥品大搜索

2020年10月8日—Proglycem(diazoxide):DrugSafetyCommunication-ReportsofPulmonaryHypertensioninInfantsandNewborns.AUDIENCE:Pulmonology ...

Proglycem (diazoxide): Drug Safety Communication - Reports of Pulmonary Hypertension in Infants and Newborns

AUDIENCE: Pulmonology, Pediatrics, Nursing, Critical Care Medicine

ISSUE: FDA is warning that a serious lung condition called pulmonary hypertension, which is high pressure in the blood vessels leading to the lungs, has been reported in infants and newborns treated with Proglycem (diazoxide) for low blood sugar. In all cases, the pulmonary hypertension resolved or improved after Proglycem was stopped. FDA is continuing to investigate this safety issue and will determine whether changes are needed in the Proglycem prescribing information.

BACKGROUND: FDA identified 11 cases of pulmonary hypertension in infants and newborns treated with diazoxide, the active ingredient in Proglycem, since the drug was approved in 1973.

RECOMMENDATION: Proglycem is usually give...